The Royal College of General Practitioners has added physical activity and lifestyle to its list of current clinical priorities.
News
Six new medicines put forward for EU nod
Six new medicines have cleared a key hurdle on the path to European approval after winning favour with regulatory advisors.
Astellas suspended from ABPI
Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) following “serious breaches” of its Code of Practice.
Pfizer completes $5.2bn acquisition of Anacor
Pfizer has completed its acquisition of Silicon Valley biotech group Anacor securing access to its flagship non-steroidal topical PDE4 inhibitor crisaborole.
Sanofi, Boehringer to swap animal, consumer health assets
Sanofi and Boehringer Ingelheim have now signed contracts to exchange their respective animal health and consumer healthcare businesses.
EU nod for Gilead’s single-pill HIV therapy
European regulators have granted marketing authorisation to Gilead’s Odefsey for the treatment of certain patients with HIV-1 infection.
NICE sticks with decision to reject Celgene’s Vidaza
Cost regulators are sticking with a decision to bar some patients with acute myeloid leukaemia from routine NHS access to Celgene’s Vidaza.
US recommends against use of AZ’ flu jab
US immunisation advisors of the Centers for Disease Control and Prevention is advising against use of AstraZeneca’s FluMist Quadrivalent for the 2016/17 influenza season.
Trulicity gets seal of approval for Welsh NHS
Eli Lilly’s once-weekly diabetes drug Trulicity (dulaglutide) has been recommend for restricted routine use on NHS Wales.
Great Britain votes to separate from European Union
The people of Great Britain have voted to exit the European Union, in a move that has sent shockwaves around the world and its markets.
Communications Team of the Year 2016 – open for entries
The PharmaTimes Communications Team of the Year competition is a fantastic learning and development opportunity for pharma communications teams, both agency and in-house.
Final NICE nod for GSK’s lupus drug Benlysta
Within the next three months patients with lupus should get ‘routine’ access to a new treatment option on the NHS in England and Wales after cost regulators issued final guidance for GlaxoSmithKline’s Benlysta.
NHS Alliance calls for pharmacy ‘forward view’
A new strategy for community pharmacy is essential to realising its full potential at the heart of community care, claims a report by New NHS Alliance.
Timely use of Novartis’ Entresto could save thousands of lives
Timely and broad adoption of Novartis’ Entresto by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone, finds a new analysis published in JAMA Cardiology.
UK pharma reiterates its ‘Remain’ plea
Representatives of the UK pharmaceutical industry have reiterated their support for Great Britain’s membership in the EU just hours before polling station’s open their doors for the referendum.
